GLG Life Tech Corporation Reports 2025 Second Quarter Financial Results

Executive Summary

• GLG Life Tech Corporation reported financial results for the three and six months ended June 30, 2025, showing a significant turnaround in net income driven by the final disposition of its former Runhai subsidiary, despite a decline in revenue due to competitive pricing pressures in the stevia market.
• The company reported a net income of $23.8 million for Q2 2025 (compared to a net loss of $3.6 million in Q2 2024) and $20.6 million for the first six months of 2025 (compared to a net loss of $8.0 million in the same period in 2024).
• Revenue decreased by 22% to $2.9 million in Q2 2025 and 16% to $6.0 million for the first half of 2025, primarily due to lower unit prices and reduced sales volumes amidst intense market competition and tariff impacts.

Key Details

• Q2 2025 Financials (Three Months Ended June 30, 2025):
  • Revenue: $2.9 million (down 22% from $3.7 million in Q2 2024).
  • Net Income from Continuing Operations: $23.8 million (up from a net loss of $3.6 million in Q2 2024).
  • Net Income Per Share: $0.62 (compared to a net loss of $0.09 per share in Q2 2024).
  • Gross Profit: $0.4 million (down 41% from $0.7 million in Q2 2024); Gross Margin: 15% (down from 20% in Q2 2024).
  • SG&A Expenses: Reduced by $0.1 million (32% decrease) to $0.3 million compared to Q2 2024.
• H1 2025 Financials (Six Months Ended June 30, 2025):
  • Revenue: $6.0 million (down 16% from $7.1 million in H1 2024).
  • Net Income from Continuing Operations: $20.6 million (up from a net loss of $8.0 million in H1 2024).
  • Net Income Per Share: $0.54 (compared to a net loss of $0.21 per share in H1 2024).
  • Gross Profit: $0.9 million (down 33% from $1.3 million in H1 2024); Gross Margin: 15% (down from 18% in H1 2024).
  • SG&A Expenses: Reduced by $0.4 million (39% decrease) to $0.6 million compared to H1 2024.
• Operational Drivers & Context:
  • The substantial increase in net income is attributed to a $27.4 million increase in other income in Q2 and a $28.6 million increase in H1, resulting from the final disposition of the Runhai subsidiary (transfer of assets and debts to Fengyang Xiaogang Hongzhang Health Industrial Park Co. Ltd).
  • Revenue declines were driven by a highly competitive pricing landscape in the stevia market, leading to decreased unit prices for products like Reb A 80, Reb A 97, and Reb M, as well as decreased units sold.
  • Cost of sales as a percentage of revenue increased to 85% in both Q2 and H1 2025 (from 80% and 82% respectively in 2024), partly due to static or increasing raw material costs against falling selling prices.
  • International (ex-China) sales comprised 100% of revenues for both periods.
• Corporate Developments & Regulatory Status:
  • The Annual General and Special Meeting was held on May 22, 2025, with shareholder approval (>99.99%) for the transfer of the Runhai subsidiary.
  • The British Columbia Securities Commission (BCSC) revoked the failure-to-file cease-trade order (FFCTO) on May 21, 2025. Management is working to resume trading on the NEX exchange.
  • The company remains listed on the NEX exchange following a delisting from the TSX effective September 3, 2024.
  • Management notes that while positive EBITDA has been achieved, the company requires an infusion of cash to realize strategic plans and avoid becoming a going concern, relying on third-party revolving loan facilities for working capital.